Analysts See $-0.13 EPS for MYOS RENS Technology Inc. (MYOS); Last Week ChemoCentryx, Inc. (CCXI) Analysts

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Analysts expect MYOS RENS Technology Inc. (NASDAQ:MYOS) to report $-0.13 EPS on March, 26.They anticipate $0.04 EPS change or 23.53% from last quarter’s $-0.17 EPS. After having $-0.12 EPS previously, MYOS RENS Technology Inc.’s analysts see 8.33% EPS growth. The stock decreased 1.90% or $0.03 during the last trading session, reaching $1.55. About 24,531 shares traded. MYOS RENS Technology Inc. (NASDAQ:MYOS) has declined 18.05% since February 24, 2018 and is downtrending. It has underperformed by 18.05% the S&P500.

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. ChemoCentryx had 4 analyst reports since September 7, 2018 according to SRatingsIntel. The firm has “Buy” rating by Canaccord Genuity given on Monday, November 12. The firm has “Buy” rating by Leerink Swann given on Thursday, February 14. See ChemoCentryx, Inc. (NASDAQ:CCXI) latest ratings:

14/02/2019 Broker: Leerink Swann Rating: Buy Initiate
11/02/2019 Broker: PiperJaffray Rating: Overweight New Target: $20 Initiates Coverage On
12/11/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $18 New Target: $20 Maintain
07/09/2018 Broker: FBR Capital Rating: Neutral New Target: $12.5 Initiates Coverage On

The stock increased 1.54% or $0.17 during the last trading session, reaching $11.24. About 113,084 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 69.59% since February 24, 2018 and is uptrending. It has outperformed by 69.59% the S&P500. Some Historical CCXI News: 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress

Since October 16, 2018, it had 0 buys, and 8 insider sales for $87.64 million activity. Schall Thomas J. sold $86,554 worth of stock or 7,211 shares. Shares for $457,747 were sold by KANAYA SUSAN M. Another trade for 30,237 shares valued at $332,779 was made by Cappel Markus J. on Friday, October 26. $85.85M worth of stock was sold by GLAXOSMITHKLINE PLC on Tuesday, October 16.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Seekingalpha.com which released: “Piper likes ChemoCentryx in premarket analyst action – Seeking Alpha” on February 11, 2019, also Seekingalpha.com with their article: “Chemocentryx secures $20M capital raise – Seeking Alpha” published on January 31, 2019, Nasdaq.com published: “ChemoCentryx to Present at the 8th Annual SVB Leerink Global Healthcare Conference – Nasdaq” on February 20, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For February 11, 2019 – Benzinga” published on February 11, 2019 as well as Seekingalpha.com‘s news article titled: “ChemoCentryx terminates previously announced common stock offering – Seeking Alpha” with publication date: September 28, 2018.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $567.91 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 45.51 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

Investors sentiment decreased to 0.98 in Q3 2018. Its down 0.61, from 1.59 in 2018Q2. It dropped, as 14 investors sold ChemoCentryx, Inc. shares while 29 reduced holdings. 13 funds opened positions while 29 raised stakes. 26.80 million shares or 1.64% more from 26.37 million shares in 2018Q2 were reported. Commercial Bank Of America De reported 101,800 shares stake. Element Management Ltd Llc holds 34,426 shares or 0.01% of its portfolio. The Georgia-based Invesco has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Adams Diversified Equity Fund Incorporated holds 0.03% or 40,200 shares. Bvf Il accumulated 7.52% or 6.77 million shares. Alps holds 0.01% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 130,929 shares. Baker Bros Ltd Partnership reported 414,029 shares. 772,281 were reported by Renaissance Technology Llc. Daiwa Secs Grp invested in 269 shares. Pennsylvania-based Vanguard Incorporated has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Citigroup Incorporated reported 4,473 shares. Metropolitan Life Insurance has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Meeder Asset invested in 0% or 3,118 shares. Panagora Asset Mngmt owns 324,114 shares. 49,177 were reported by Schwab Charles Invest Mngmt.

More notable recent MYOS RENS Technology Inc. (NASDAQ:MYOS) news were published by: Globenewswire.com which released: “Report: Exploring Fundamental Drivers Behind Crocs, Portola Pharmaceuticals, ANSYS, Alpha and Omega Semiconductor, PetMed Express, and MYOS RENS Technology — New Horizons, Emerging Trends, and Upcoming Developments – GlobeNewswire” on February 19, 2019, also Prnewswire.com with their article: “MYOS RENS Technology Announces First Endorsement Deal for Yolked® with NBA Superstar Aaron Gordon – PRNewswire” published on February 07, 2019, Nasdaq.com published: “MYOS Muscling Up, CORT Turns Heads, Former FDA Official Joins PTE Board – Nasdaq” on December 11, 2018. More interesting news about MYOS RENS Technology Inc. (NASDAQ:MYOS) were released by: Seekingalpha.com and their article: “Myos Rens up 51% on launch of new sports nutrition product – Seeking Alpha” published on December 11, 2018 as well as Benzinga.com‘s news article titled: “Myos (NASDAQ:MYOS) Shares Find Nourishment From Vitamin Shoppe (NYSE:VSI) Distribution Deal – Benzinga” with publication date: December 11, 2018.

MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company has market cap of $11.58 million. The firm primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. It currently has negative earnings. The Company’s products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *